Published in Proc Natl Acad Sci U S A on April 26, 2004
A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet (2006) 7.89
LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science (2009) 5.23
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A (2005) 4.56
Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci (2007) 3.59
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest (2006) 3.54
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A (2009) 3.39
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet (2006) 3.38
The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov (2012) 3.18
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A (2005) 3.15
Validating therapeutic targets through human genetics. Nat Rev Drug Discov (2013) 2.94
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol (2005) 2.42
Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation (2013) 2.03
Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res (2008) 1.98
Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A (2008) 1.86
Hepatic proprotein convertases modulate HDL metabolism. Cell Metab (2007) 1.68
Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem (2009) 1.67
Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem (2009) 1.65
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res (2010) 1.56
Genetics: a gene of rare effect. Nature (2013) 1.54
The PCSK9 decade. J Lipid Res (2012) 1.50
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circ Cardiovasc Genet (2015) 1.50
Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem (2009) 1.49
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J (2007) 1.48
The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J Biol Chem (2010) 1.44
Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond) (2010) 1.43
Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor. PLoS One (2016) 1.42
The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci U S A (2007) 1.29
The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions. J Biol Chem (2013) 1.27
Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol (2011) 1.20
A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One (2010) 1.19
Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR. J Lipid Res (2012) 1.18
Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J Lipid Res (2008) 1.18
Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One (2013) 1.18
In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem (2010) 1.18
The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor. Genes Dev (2011) 1.17
PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep (2008) 1.17
Screening the mammalian extracellular proteome for regulators of embryonic human stem cell pluripotency. Proc Natl Acad Sci U S A (2010) 1.17
Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci U S A (2009) 1.12
Similarities and differences in structure, expression, and functions of VLDLR and ApoER2. Mol Neurodegener (2011) 1.06
Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. J Biol Chem (2010) 1.04
Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One (2012) 1.04
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis (2011) 1.03
PCSK9 function and physiology. J Lipid Res (2008) 1.03
Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun (2008) 1.02
A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models. Toxicol Sci (2012) 1.02
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J Lipid Res (2011) 1.01
Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J Biol Chem (2012) 1.00
The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis (2011) 0.98
The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. J Biol Chem (2012) 0.96
Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. J Biol Chem (2015) 0.95
The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther (2013) 0.94
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res (2014) 0.94
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res (2009) 0.93
FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression. J Biol Chem (2013) 0.93
PCSK9 function and physiology. J Lipid Res (2008) 0.92
FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors. Proc Natl Acad Sci U S A (2011) 0.92
Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly. BMC Cell Biol (2007) 0.92
Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke. PLoS One (2007) 0.92
PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. J Lipid Res (2010) 0.91
Isolation and characterization of the circulating truncated form of PCSK9. J Lipid Res (2014) 0.90
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis. JAMA (2016) 0.89
Molecular population genetics of PCSK9: a signature of recent positive selection. Pharmacogenet Genomics (2008) 0.88
Molecular genetics of coronary artery disease. J Hum Genet (2015) 0.87
Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. J Biol Chem (2012) 0.87
Genetic variation at the proprotein convertase subtilisin/kexin type 5 gene modulates high-density lipoprotein cholesterol levels. Circ Cardiovasc Genet (2009) 0.87
The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis. J Biol Chem (2014) 0.86
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. J Lipid Res (2014) 0.86
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol (2015) 0.85
Profile of evolocumab and its potential in the treatment of hyperlipidemia. Drug Des Devel Ther (2015) 0.85
Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. J Lipid Res (2015) 0.85
Proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism interacts with alcohol consumption to modulate serum lipid levels. Int J Med Sci (2012) 0.84
Liver X receptor beta and thyroid hormone receptor alpha in brain cortical layering. Proc Natl Acad Sci U S A (2010) 0.84
Lysine acetylation in the lumen of the ER: a novel and essential function under the control of the UPR. Biochim Biophys Acta (2012) 0.83
Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice. J Lipid Res (2015) 0.83
The genetic and molecular bases of monogenic disorders affecting proteolytic systems. J Med Genet (2005) 0.83
New developments in atherosclerosis: clinical potential of PCSK9 inhibition. Vasc Health Risk Manag (2015) 0.83
PCSK9 Association With Lipoprotein(a). Circ Res (2016) 0.82
On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis (2014) 0.82
PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice. J Lipid Res (2015) 0.82
Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species. PLoS One (2007) 0.82
A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine (2015) 0.82
Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9. Lipids Health Dis (2013) 0.82
Local effects of human PCSK9 on the atherosclerotic lesion. J Pathol (2015) 0.82
microRNA regulation of lipoprotein metabolism. Curr Opin Lipidol (2014) 0.82
Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9. J Biomed Res (2015) 0.82
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation. J Biol Chem (2016) 0.81
Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. J Lipid Res (2015) 0.81
Proprotein convertases in high-density lipoprotein metabolism. Biomark Res (2013) 0.80
Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9. J Biol Chem (2014) 0.80
PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers. Clin Cardiol (2017) 0.80
PCSK9 inhibitors in the prevention of cardiovascular disease. J Thromb Thrombolysis (2016) 0.79
Both rare and common variants in PCSK9 influence plasma low-density lipoprotein cholesterol level in American Indians. J Clin Endocrinol Metab (2014) 0.79
β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells. FEBS J (2015) 0.78
Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9. J Biol Chem (2015) 0.78
Human Serum PCSK9 Is Elevated at Parturition in Comparison to Nonpregnant Subjects While Serum PCSK9 from Umbilical Cord Blood is Lower Compared to Maternal Blood. ISRN Endocrinol (2013) 0.78
New Era of Lipid-Lowering Drugs. Pharmacol Rev (2016) 0.77
Opening up new fronts in the fight against cholesterol. Elife (2013) 0.77
Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain. PLoS One (2016) 0.77
High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels. Atherosclerosis (2015) 0.77
A receptor-mediated pathway for cholesterol homeostasis. Science (1986) 19.28
Regulation of the mevalonate pathway. Nature (1990) 18.25
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet (2003) 11.67
Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest (1993) 9.56
Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A (2003) 8.20
The PROSITE database, its status in 1997. Nucleic Acids Res (1997) 8.12
Arg-Gly-Asp: a versatile cell recognition signal. Cell (1986) 7.89
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A (2003) 5.26
Subtilases: the superfamily of subtilisin-like serine proteases. Protein Sci (1997) 4.86
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest (2003) 4.42
Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res (1999) 3.79
Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. BMJ (1997) 3.51
Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res (2003) 2.75
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet (2004) 2.53
Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain. Mol Cell (2003) 2.40
Mammalian subtilisin/kexin isozyme SKI-1: A widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. Proc Natl Acad Sci U S A (1999) 2.37
Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins. Biochemistry (1991) 2.34
Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse. J Clin Invest (1995) 2.04
RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors. EMBO J (1996) 2.02
Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science (1994) 1.95
Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci U S A (1995) 1.90
Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res (1990) 1.90
Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys (2003) 1.88
The cholesterol-regulated StarD4 gene encodes a StAR-related lipid transfer protein with two closely related homologues, StarD5 and StarD6. Proc Natl Acad Sci U S A (2002) 1.76
Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption. Proc Natl Acad Sci U S A (1998) 1.73
Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins. J Biol Chem (1999) 1.65
The role of O-linked sugars in determining the very low density lipoprotein receptor stability or release from the cell. FEBS Lett (1999) 1.58
Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications. J Mol Endocrinol (2000) 1.54
Differential glycosylation regulates processing of lipoprotein receptors by gamma-secretase. J Biol Chem (2003) 1.48
A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am J Hum Genet (1999) 1.34
Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred. J Lipid Res (1999) 1.17
Effects of dietary cholesterol on serum cholesterol: a meta-analysis and review. Am J Clin Nutr (1992) 1.09
Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J Clin Invest (1995) 1.04
Men classified as hypo- or hyperresponders to dietary cholesterol feeding exhibit differences in lipoprotein metabolism. J Nutr (2003) 1.02
Subtilisin-related serine proteases in the mammalian constitutive secretory pathway. Semin Cell Dev Biol (1998) 1.00
Ammonium chloride causes reversible inhibition of low density lipoprotein receptor recycling and accelerates receptor degradation. J Biol Chem (1990) 0.99
Soluble LDL-R are formed by cell surface cleavage in response to phorbol esters. Eur J Biochem (2004) 0.97
Low density lipoprotein receptor degradation is influenced by a mediator protein(s) with a rapid turnover rate, but is unaffected by receptor up- or down-regulation. J Lipid Res (1988) 0.94
Low-density-lipoprotein receptors in human fibroblasts are not degraded in lysosomes. Biochem J (1989) 0.89
Whole population, genome-wide mapping of hidden relatedness. Genome Res (2008) 4.72
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A (2005) 3.15
Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res (2003) 2.75
Recipes for creating animal models of diabetic cardiovascular disease. Circ Res (2007) 2.34
Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (2002) 2.13
Evaluating potential for whole-genome studies in Kosrae, an isolated population in Micronesia. Nat Genet (2006) 2.07
Genome-wide association studies in an isolated founder population from the Pacific Island of Kosrae. PLoS Genet (2009) 2.02
Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci U S A (2004) 2.00
Genome-wide association study of electrocardiographic conduction measures in an isolated founder population: Kosrae. Heart Rhythm (2009) 1.91
StAR-related lipid transfer (START) proteins: mediators of intracellular lipid metabolism. J Biol Chem (2003) 1.88
Vitamin D may not improve lipid levels: a serial clinical laboratory data study. Circulation (2012) 1.85
The cholesterol-regulated StarD4 gene encodes a StAR-related lipid transfer protein with two closely related homologues, StarD5 and StarD6. Proc Natl Acad Sci U S A (2002) 1.76
Intracellular cholesterol transport. Arterioscler Thromb Vasc Biol (2004) 1.75
Induction of atherosclerosis by low-fat, semisynthetic diets in LDL receptor-deficient C57BL/6J and FVB/NJ mice: comparison of lesions of the aortic root, brachiocephalic artery, and whole aorta (en face measurement). Arterioscler Thromb Vasc Biol (2003) 1.67
Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13. Arterioscler Thromb Vasc Biol (2008) 1.63
DASH: a method for identical-by-descent haplotype mapping uncovers association with recent variation. Am J Hum Genet (2011) 1.62
A phenotype-sensitizing Apoe-deficient genetic background reveals novel atherosclerosis predisposition loci in the mouse. Genetics (2002) 1.61
Linkage analysis of quantitative traits for obesity, diabetes, hypertension, and dyslipidemia on the island of Kosrae, Federated States of Micronesia. Proc Natl Acad Sci U S A (2006) 1.48
Crystal structure of the Mus musculus cholesterol-regulated START protein 4 (StarD4) containing a StAR-related lipid transfer domain. Proc Natl Acad Sci U S A (2002) 1.47
The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-kappaB target genes. Proc Natl Acad Sci U S A (2007) 1.45
Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med (2011) 1.44
Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and reversal by a fish oil diet. Circ Res (2009) 1.39
A20, a regulator of NFkappaB, maps to an atherosclerosis locus and differs between parental sensitive C57BL/6J and resistant FVB/N strains. Proc Natl Acad Sci U S A (2003) 1.38
In silico quantitative trait locus map for atherosclerosis susceptibility in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2003) 1.38
Differential gene regulation of StarD4 and StarD5 cholesterol transfer proteins. Activation of StarD4 by sterol regulatory element-binding protein-2 and StarD5 by endoplasmic reticulum stress. J Biol Chem (2005) 1.32
Trib1 is a lipid- and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice. J Clin Invest (2010) 1.32
Atherosclerosis quantitative trait loci are sex- and lineage-dependent in an intercross of C57BL/6 and FVB/N low-density lipoprotein receptor-/- mice. Proc Natl Acad Sci U S A (2005) 1.31
High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol (2004) 1.30
Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. Curr Opin Lipidol (2005) 1.28
The short-term effects of vitamin D repletion on cholesterol: a randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol (2012) 1.21
How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep (2013) 1.20
Inactive lipoprotein lipase (LPL) alone increases selective cholesterol ester uptake in vivo, whereas in the presence of active LPL it also increases triglyceride hydrolysis and whole particle lipoprotein uptake. J Biol Chem (2001) 1.13
Systematic haplotype analysis resolves a complex plasma plant sterol locus on the Micronesian Island of Kosrae. Proc Natl Acad Sci U S A (2009) 1.13
Vitamin D-binding protein levels do not influence the effect of vitamin D repletion on serum PTH and calcium: data from a randomized, controlled trial. J Clin Endocrinol Metab (2014) 1.07
Loci on chromosomes 14 and 2, distinct from ABCG5/ABCG8, regulate plasma plant sterol levels in a C57BL/6J x CASA/Rk intercross. Proc Natl Acad Sci U S A (2002) 1.06
Two Hsp70 family members expressed in atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.02
Quantitative trait locus mapping of genetic modifiers of metabolic syndrome and atherosclerosis in low-density lipoprotein receptor-deficient mice: identification of a locus for metabolic syndrome and increased atherosclerosis on chromosome 4. Arterioscler Thromb Vasc Biol (2004) 1.00
Increased power of mixed models facilitates association mapping of 10 loci for metabolic traits in an isolated population. Hum Mol Genet (2010) 0.98
Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice. J Lipid Res (2009) 0.98
Increased ADAM17 mRNA expression and activity is associated with atherosclerosis resistance in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol (2008) 0.96
Targeted disruption of steroidogenic acute regulatory protein D4 leads to modest weight reduction and minor alterations in lipid metabolism. J Lipid Res (2009) 0.95
Athsq1 is an atherosclerosis modifier locus with dramatic effects on lesion area and prominent accumulation of versican. Arterioscler Thromb Vasc Biol (2008) 0.95
A complex plasma plant sterol locus on mouse chromosome 14 has at least two genes regulating intestinal sterol absorption. J Lipid Res (2006) 0.95
Cholesterol feeding of mice expressing cholesterol 7alpha-hydroxylase increases bile acid pool size despite decreased enzyme activity. Proc Natl Acad Sci U S A (2004) 0.95
Candidate genes involved in cardiovascular risk factors by a family-based association study on the island of Kosrae, Federated States of Micronesia. Am J Med Genet (2002) 0.94
Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults. J Nutr (2010) 0.94
Hyperglycemic Ins2AkitaLdlr⁻/⁻ mice show severely elevated lipid levels and increased atherosclerosis: a model of type 1 diabetic macrovascular disease. J Lipid Res (2011) 0.93
The mouse atherosclerosis locus at chromosome 10 (Ath11) acts early in lesion formation with subcongenic strains delineating 2 narrowed regions. Arterioscler Thromb Vasc Biol (2010) 0.92
Loci controlling plasma non-HDL and HDL cholesterol levels in a C57BL /6J x CASA /Rk intercross. J Lipid Res (2003) 0.91
Novel strategy using F1-congenic mice for validation of QTLs: studies at the proximal chromosome 10 atherosclerosis susceptibility locus. Arterioscler Thromb Vasc Biol (2009) 0.90
Phytosterolemia on the island of Kosrae: founder effect for a novel ABCG8 mutation results in high carrier rate and increased plasma plant sterol levels. J Lipid Res (2004) 0.89
Altered expression of Raet1e, a major histocompatibility complex class 1-like molecule, underlies the atherosclerosis modifier locus Ath11 10b. Circ Res (2013) 0.89
Identification of quantitative trait loci affecting body composition in a mouse intercross. Proc Natl Acad Sci U S A (2006) 0.89
Localization of the PE methylation pathway and SR-BI to the canalicular membrane: evidence for apical PC biosynthesis that may promote biliary excretion of phospholipid and cholesterol. J Lipid Res (2003) 0.84
A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis (2003) 0.83
European admixture on the Micronesian island of Kosrae: lessons from complete genetic information. Eur J Hum Genet (2009) 0.83
STARD4 knockdown in HepG2 cells disrupts cholesterol trafficking associated with the plasma membrane, ER, and ERC. J Lipid Res (2012) 0.82
Vitamin D3 repletion in chronic kidney disease stage 3: effects on blood endotoxin activity, inflammatory cytokines, and intestinal permeability. Ren Fail (2013) 0.80
Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice. Atherosclerosis (2004) 0.79
Plasma plant sterol levels: another coronary heart disease risk factor? Arterioscler Thromb Vasc Biol (2005) 0.77
Antibodies to PCSK9: a superior way to lower LDL cholesterol? Circ Res (2012) 0.75
Two loci on chromosome 9 control bile acid composition: evidence that a strong candidate gene, Cyp8b1, is not the culprit. J Lipid Res (2006) 0.75
Longitudinal study shows increasing obesity and hyperglycemia in micronesia. Obesity (Silver Spring) (2013) 0.75